NASDAQ:PTCTPTC Therapeutics Stock Price, Forecast & News

PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTCT stock has increased by 18.8% and is now trading at $55.93. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PTC Therapeutics.

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for PTC Therapeutics.

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.00) by $0.81. The biopharmaceutical company had revenue of $68.30 million for the quarter, compared to analysts' expectations of $81.90 million. PTC Therapeutics had a negative return on equity of 46.42% and a negative net margin of 90.83%. PTC Therapeutics's revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.29) EPS. View PTC Therapeutics' earnings history.

8 analysts have issued 12-month price targets for PTC Therapeutics' stock. Their forecasts range from $45.00 to $85.00. On average, they expect PTC Therapeutics' share price to reach $62.83 in the next twelve months. This suggests a possible upside of 12.3% from the stock's current price. View analysts' price targets for PTC Therapeutics.

Media coverage about PTCT stock has trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PTC Therapeutics earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about PTC Therapeutics.

Some companies that are related to PTC Therapeutics include Sarepta Therapeutics (SRPT), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), ACADIA Pharmaceuticals (ACAD), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC), Regulus Therapeutics (RGLS), NVIDIA (NVDA), Cisco Systems (CSCO), Aduro BioTech (ADRO) and Gilead Sciences (GILD).

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.01%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View institutional ownership trends for PTC Therapeutics.

PTCT stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. View insider buying and selling activity for PTC Therapeutics.

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTCT stock can currently be purchased for approximately $55.93.

PTC Therapeutics has a market capitalization of $3.66 billion and generates $306.98 million in revenue each year. The biopharmaceutical company earns $-251,580,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe.

The official website for PTC Therapeutics is www.ptcbio.com.

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]